Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13951MR)

This product GTTS-WQ13951MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13951MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7061MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ2763MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ7065MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
GTTS-WQ7436MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ75MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ9841MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ8357MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ11115MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MDX-060
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW